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Rhabdomyolysis (RM) is a clinical emergency characterized by fulminant skeletal muscle damage and release of
intracellular muscle components into the blood stream leading to myoglobinuria and, in severe cases, acute renal
failure. Apart from trauma, a wide range of causes have been reported including drug abuse and infections.
Underlying genetic disorders are also a cause of RM and can often pose a diagnostic challenge, considering their
marked heterogeneity and comparative rarity.
In this paper we review the range of rare genetic defects known to be associated with RM. Each gene has been
reviewed for the following: clinical phenotype, typical triggers for RM and recommended diagnostic approach. The
purpose of this review is to highlight the most important features associated with specific genetic defects in order
to aid the diagnosis of patients presenting with hereditary causes of recurrent RM.
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A rabdomiólise (RM) é um evento agudo e grave, caracterizado por danos do músculo esquelético com a liberação,
em grande quantidade, de componentes intracelulares para a corrente sanguínea. Uma vasta gama de causas tem
sido relatada, incluindo trauma, abuso de drogas e infecções. Doenças hereditárias também podem causar RM,
mas muitas vezes representam um desafio diagnóstico, considerando a sua heterogeneidade e raridade. Por fim,
diversas doenças neuromusculares costumam estar associadas com níveis de CK cronicamente elevados,
dificultando a identificação correta dos episódios de RM.
Nesse artigo, revisamos os diversos defeitos genéticos associados à RM. Cada gene foi revisado abrangendo os
seguintes: fenótipo clínico, gatilhos para RM e abordagem diagnóstica. O objetivo desta revisão é destacar as
características mais importantes associados a defeitos genéticos específicos, a fim de auxiliar o diagnóstico de
pacientes com causas hereditárias de RM recorrente.Introduction
Rhabdomyolysis (RM) is characterised by acute and often
severe skeletal muscle damage resulting in the release of
intracellular muscle components into the blood stream
frequently resulting in myoglobinuria and, in severe cases,
acute renal failure. Diverse etiologies (Figure 1) implicated
in acute RM share a common final pathway, increased* Correspondence: renata_scalco@hotmail.com
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death through the activation of a number of detrimental
mechanisms such as enzymatic activation and prolonged
muscle fibre contraction [1,2]. Different genetic defects
causing various neuromuscular and metabolic disorders
are known to be associated with RM. Recurrent RM, exer-
cise related complaints and a positive family history are
common features of an underlying genetic condition. In
some instances, RM may be due to a combination of
genetic predisposition and environmental causes. In these
cases a purely environmental factor may be considered the
sole cause for the acute event with a relatively high risk
of recurrence if the genetic diagnosis is not considered.ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Figure 1 Examples of conditions associated with RM. In individual cases both genetic and environmental factors may combine to trigger a RM event;
anaesthesia-induced RM is the best characterized example. VLCAD: very long-chain acyl-CoA dehydrogenase, CPTII: carnitine palmitoyl-transferase-II,
MAD: multiple acyl-CoA dehydrogenase, GSD: glycogen storage disease, tRNA: Transfer Ribonucleic Acid, DGUOK: deoxyguanosine kinase gene, RYR1:
Ryanodine Receptor 1 gene, SIL1: SIL1, S. Cerevisiae, homolog of, TSEN54: tRNA splicing endonuclease 54 gene, S. cerevisiae, homolog of, DMD:
Duchenne Muscular Dystrophy, BMD: Becker Muscular Dystrophy, ANO5:Anoctamin 5 gene, LGMD: Limb-girdle Muscular Dystrophy, DYSF:
Dysferlin gene, FKRP: fukutin-related protein gene [1,2,4,8,62,110-113].
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with “virally-induced” RM who in fact had malignant
hyperthermia susceptibility (MHS)-associated RYR1 muta-
tions, resulting in a genetic predisposition for the virally-
triggered muscle breakdown [3,4].
Identifying underlying genetic disorders presenting with
RM can pose a diagnostic challenge due to their rarity and
marked heterogeneity, requiring a high degree of clinical
suspicion for appropriate investigation to be requested. Al-
though difficult, establishing a genetic diagnosis in a patient
presenting with RM is of great clinical importance to give
appropriate advice and to prevent future episodes. More re-
cently Zutt et al. (2014) suggested an algorithm for the clin-
ical diagnostic approach to recurrent RM [2] whereas the
present review will focus on the approach to a specific gen-
etic diagnosis. Here we review the genetic defects known to
be associated with RM, many of them are rare and very rare
(summarized in Table 1). The purpose of this review is to
highlight the most important features in order to aid the
genetic diagnosis of patients with unexplained, in particular
recurrent RM episodes (Figures 2 and 3).
Metabolic disorders
Inherited metabolic disorders of skeletal muscle are rare
conditions that can be divided into those disorders causedby abnormal glycogen storage affecting muscle and disor-
ders of fatty acid oxidation. In metabolic myopathies, ex-
ploring patients’ symptoms in relation to the timing and
type of exercise will provide a strong clinical clue. The
other clue to a metabolic diagnosis is that symptoms are
experienced in all skeletal muscles including, neck, jaw,
arms, paraspinals and legs. In disorders of glycogenolysis
(such as McArdle disease) and glycolysis (such as Tarui
disease) symptoms are induced within minutes by isomet-
ric muscle contraction (such as weight lifting), intense
maximal exercise (such as sprinting) or within a few mi-
nutes of aerobic physical activity (such as walking). By
contrast, in disorders of fatty acid metabolism symptoms
occur only after aerobic exercise for a more prolonged
period (over 45 minutes and often after several hours). In
addition, fever, fasting and stress can induce symptoms.
Symptoms are not triggered by isometric contraction in
people with fatty acid metabolism dysfunction. Thus, a de-
tailed medical history with careful consideration of the
precipitating factors is essential for the correct diagnosis
to be made. However, phenotypic variations do exist, for
example in glycogen storage disorder type XIV, caused by
recessive mutations in PGM1, where additional dys-
morphic and systemic features such as bifid uvula, cleft
palate, liver disease and growth retardation are prominant
Table 1 Inherited neuromuscular disorders associated with episodes of rhabdomyolysis
Gene Disease name Baseline CK levels Pattern of
inheritance
Trigger for rhabdomyolysis
Disorders of glycogen metabolism
PYGM Glycogen storage disease type V,
McArdle disease
High AR Aerobic and anaerobic exercise,
symptom onset within minutes
PFKM Glycogen storage disease type VII,
Tarui’s disease
High AR Aerobic and anaerobic exercise,
symptom onset within minutes
ALDOA Glycogen storage disease type XII Normal AR Febrile illness, infection
Mild elevation, High
ENO3 Glycogen storage disease type XIII Normal AR Aerobic and anaerobic exercise,
symptom onset within minutes
High
PGAM2 Glycogen storage disease type X High AR Aerobic and anaerobic exercise,
symptom onset within minutes
PGK1 Phosphoglycerate kinase 1 deficiency Normal X-linked Aerobic and anaerobic exercise,
symptom onset within minutes
High
PGM1 Glycogen storage disease type XIV High AR Aerobic and anaerobic exercise, symptom
onset within minutes, general anaesthesia
PHKA1 Glycogen storage disease type IX ? X-linked Aerobic and anaerobic exercise, symptom
onset within minutes
PHKB AR
Disorders of fatty acid metabolism:
ACADVL Deficiency of very-long-chain acyl-CoA
dehydrogenase
Normal AR Fasting, prolonged exercise, cold, infections,
fever
High
CPT2 Carnitine palmitoyl-transferase deficiency Normal AR Prolonged exercise, fasting, fever, infection,
high fat intake, cold exposure, heat,
emotional stress, drugs
ETFA Glutaric aciduria Type II Normal AR Physical exercise, fasting, irregular diet
or infection
ETFB Multiple acyl-coenzyme A
dehydrogenase deficiency
Mildly to moderately
elevated
ETFDH
Mitochondrial disorders
COI
(MTCO1)
Mitochondrial disorder Normal Maternal
inheritance
Prolonged or repetitive exercise
COII Mitochondrial disorder Normal Maternal
inheritance
Exercise
(MTCO2)
COIII
(MTCO3)
Mitochondrial disorder Normal Maternal
inheritance
Prolonged exercise, viral illness,
unknown cause
DGUOK Mitochondrial disorder ? AR Viral illness
FDX1L Mitochondrial disorder Normal AR ? After exercise [114]
High
HADHA Mitochondrial Trifunctional Protein
Deficiency
Normal AR Strenuous physical activity
HADHB
ISCU Iron–sulphur cluster deficiency
myopathy (Mitochondrial disorder)
? AR Exercise
MTCYB Mitochondrial disorder Normal ?Sporadic
mutations [64]
Exercise
POLG1 1 case report of rhabdomyolysis in association with PIS [73] AD, AR PIS
Disorders of intramuscular calcium release and excitation-contraction coupling
RYR1 Malignant hyperthermia-susceptibility,
Exertional rhabdomyolysis, Congenital
myopathy
Normal or mildly to
moderately elevated
(usually <1000 IU/L)
AD, AR Heat, infection, alcohol, drugs, anaesthetic
(MHS) and exercise
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Table 1 Inherited neuromuscular disorders associated with episodes of rhabdomyolysis (Continued)
Muscular dystrophies
ANO5 Anoctaminopathy-5 High AR Unprovoked – no trigger has been
identified
DMD Duchenne muscular dystrophy, Becker
muscular dystrophy
High X-linked Exercise, anaesthetic drugs
DYSF LGMD2B, Miyoshi myopathy High AR Exercise
FKTN Fukuyama congenital muscular dystrophy High AR One case following the use of halothane
and succinylcholine [89,90]
FKRP LGMD2I High AR Exercise [82]
Miscellaneous
LPIN1 Phosphatidic acid phosphatase deficiency Normal, High AR Febrile illness, anaesthesia and fasting.
SIL1 Marinesco-Sjogren syndrome Normal, High AR Febrile infection
TSEN54 Pontocerebellar hypoplasia type 2 Normal, High AR Hyperthermia
The table above summarises genes, disease name, baseline serum CK levels (between acute episodes of rhabdomyolysis), pattern of inheritance and triggers for
rhabdomyolysis. Genes commonly associated with rhabdomyolysis episodes are indicated in bold.
CK: creatine kinase; AR: autosomal recessive; AD: autosomal dominant; MHS: malignant hyperthermia susceptibility; PIS: propofol infusion syndrome; LGMD: limb-girdle
muscular dystrophy (2B and 2I).
Figure 2 Examples of different triggers of rhabdomyolysis. The identification of triggers may help guiding genetic testing and may also aid the
interpretation of variants of uncertain significance identified on next generation sequencing in patients presenting with RM. CK: creatine kinase,
12MWT: 12 minute walk test, FBC: full blood count, MRI: magentic resonance imaging.
Scalco et al. Orphanet Journal of Rare Diseases  (2015) 10:51 Page 4 of 15
Muscle Biopsy 
Lipid 
Storage 
Glycogen 
Storage 
Glycogen + 
Polyssacharide 
Storage 
Features of 
Mitochondrial 
Disease 
Dystrophic 
Features 
Tubular 
Aggregates 
Core 
Myopathy 
Amyloid 
Deposition 
Inflammatory 
Infiltration 
ACADVL ENO3 PFKM COI (MTCO1) ANO5 PGAM2 RYR1 ANO5 DYSF 
CPT2 PGAM2  COII (MTCO2) DYS     
ETFA PGK1  COIII (MTCO3) DYSF     
ETFB PGM1  DGUOK FKTN     
ETFDH PHKA1  ISCU FKRP     
ALDOA PHKB  MTCYB 
HADHA PYGM  POLG1 
HADHB         
Non-specific 
Features 
Potentially any 
of the above 
Figure 3 Muscle biopsy patterns associated with hereditary causes of RM. Muscle biopsy features may provide a guide to targeted genetic testing.
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general symptoms of metabolic myopathies and the spe-
cific phenotypic variations of specific genetic defects is es-
sential to guide further investigations.
Thus, despite recent advances in the genetic diagnosis,
a detailed targeted medical history remains the most im-
portant initial step for identifying the underlying inherited
metabolic causes of RM and to aid choice of invasive diag-
nostic investigations such as skin (in suspected fatty acid
oxidation disorders) and muscle biopsy, for tissue histo-
chemistry and/or biochemical analysis (in suspected glyco-
gen storage disorders). In the majority of these conditions,
inheritance is autosomal-recessive, with only few condi-
tions inherited in an X-linked, autosomal-dominant or
mitochondrial fashion.
Disorders of glycogen metabolism
A variety of enzymes are involved in glycogen metabol-
ism, an important energy source for skeletal muscle dur-
ing isometric, anaerobic exercise, aerobic glycolysis and
strenuous exertion. Genetic defects leading to absence
or severe deficiency of these enzymes cause impaired
glycogen breakdown, resulting in exercise intolerance
and RM. In addition, in some of these glycogen storage
disorders (GSDs) enzymes are expressed in tissues other
than skeletal muscle, leading to other clinical manifesta-
tions such as haemolytic anaemia, brain and skin in-
volvement. A feature of these conditions is a suboptimal
rise in lactate during exercise and exaggerated rise in
ammonia in McArdle disease. Diagnosis is dependent
upon biochemical analysis of muscle tissue which reveals
the reduced enzyme activity. Diagnosis is confirmed by
genetic studies.McArdle disease (GSDV) is the most common dis-
order in this group, and it will therefore be reviewed in
more detail. Other types of GSDs are extremely rare and
their features will only be briefly summarized.
Muscle Glycogen Phosphorylase (PYGM)
Homozygous or compound heterozygous mutations in
PYGM (OMIM #608455) cause glycogen storage disease
type V (GSDV, McArdle disease) which is characterized by
the absence of skeletal muscle glycogen phosphorylase,
resulting in an inability to convert muscle glycogen into
glucose-1-phosphate [6,7]. As a result, glycogen accumu-
lates in skeletal muscle.
Phenotype Exercise intolerance presenting as muscle fa-
tigue, discomfort and cramps within minutes of exertion,
commonly associated with a disproportionate increased
in heart rate (HR) [8,9]. Symptoms are more severe with
strenuous exercise such as climbing stairs or walking up
hills and isometric contraction (heavy lifting or squat-
ting) [10]. Prolonged muscle spasm (muscle contracture)
is not uncommon and can lead to RM. The second wind
phenomenon is characterized by symptoms easing and
an associated decrease in HR leading to an improvement
in exercise tolerance occurring at around 8–10 minutes
of aerobic exertion. It is the hallmark of this condition
and is due to improved blood flow resulting in improved
availability of glucose release from the hepatic glycogen
stores and fatty acid oxidation metabolism [11]. Other
clinical features may include muscle hypertrophy. Fixed
weakness predominantly affecting shoulder girdle and
axial (paraspinal) muscles is another feature of GSDV
usually seen in older patients [9,10]. GSDV symptoms
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experience several episodes of myoglobinuria and RM
before the diagnosis is confirmed [12].
Triggers for Rhabdomyolysis Persistent skeletal muscle
activity despite symptoms (before getting into the second
wind phenomenon), intense exertion, anaerobic activity, iso-
metric contraction and sustained muscle contracture [13,14].
Diagnostic approach Serum CK is almost always raised,
often >1,000 IU/L. Muscle biopsy shows subsarcolemmal
vacuoles with glycogen accumulation and the absence (or
virtual absence in rare cases) of muscle glycogen phos-
phorylase activity demonstrated by muscle histochemistry
and/or muscle biochemical enzyme analysis [15]. Func-
tional testing using either cycle test or 12 minute walk test
can be used to demonstrate the presence of the second
wind phenomenon [16]. Forearm exercise test shows sub-
optimal (<3 fold) increase in serum lactate with a normal
rise in ammonia [17]. Non-ischaemic exercise test is pre-
ferred because of the risk of contracture and compartment
syndrome in people with McArdle disease.
Phosphofructokinase, Muscle Type (PFKM)
Autosomal-recessive mutations in the PFKM gene (OMIM
#610681) cause GSD type VII, or Tarui’s disease, a metabolic
myopathy characterized by phosphofructokinase (PFK)
deficiency resulting in impaired conversion of fructose-6-
phosphate to fructose-1.6-diphosphate, affecting both an-
aerobic and aerobic glycolysis. In general, GSDVII shares
similar presentation with GSDV (see above) except that
GSDVII presents with more severe exercise intolerance.
Phenotype Similar to GSDV but there is no second
wind phenomenon. In fact, unlike GSDV where oral ad-
ministration of glucose immediately prior to exercise can
improve exercise tolerance, in Tarui disease it exacerbates
exercise intolerance leading to an ‘out-of-wind phenomenon’
by impairing fatty acid oxidation [18]. Atypical variants re-
ported include severe infantile form with arthrogryposis, a
form presenting with fixed myopathy and haemolytic an-
aemia without muscle symptoms. Hypertrophic cardiomy-
opathy has been reported in one patient [15,18-20].
Triggers for Rhabdomyolysis Exercise and isometric
muscle contraction [20].
Diagnostic approach The combination of haemolytic an-
aemia and myopathy should raise the suspicion of GSDVII
[18,20]. The combination of haemolytic anaemia and
muscle symptoms can also be associated with GSDXII
and phosphoglycerate kinase deficiency described below.
Serum CK is usually raised and forearm exercise test
reveals a suboptimal increase in lactate. As in McArdledisease, hyperuricaemia and gout are more frequent.
Muscle biopsy shows a vacuolar myopathy with polygluco-
san accumulation demonstrated by positive periodic acid-
Schiff (PAS) staining but resistant to diastase digestion
[18] and weak/negative PFK histochemistry [15,18,20]. En-
zyme biochemical analysis shows reduced enzyme activity
in muscle and, in some patients, in erythrocytes [20].
Aldolase A, Fructose-bisphosphate (ALDOA)
GSDXII or aldolase A deficiency is a very rare metabolic
disorder characterized by the deficiency of the aldolase A
isoform which converts fructose 1,6-biphosphate into dihy-
droxyacetone phosphate and glyceraldehydes 3-phosphate.
As a result, glycolysis is affected in muscle and erythro-
cytes. GSDXII is caused by autosomal-recessive mutations
in the ALDOA gene (OMIM #103850).
Phenotype Non-spherocytic haemolytic anaemia. Rare
cases with myopathic manifestations including muscle
pain and weakness, exercise intolerance and RM [21,22].
RM may be seen during the first months of life [23].
Triggers for Rhabdomyolysis Febrile illness [21-23] and
infection [24].
Diagnostic approach Reduced red blood cell aldolase in
combination with high serum CK suggest the diagnosis
[22,25]. Muscle biochemistry shows reduced aldolase ac-
tivity [21]. The spectrum of histopathological findings in
GSDXII and their clinical relevance are currently unclear.
In one patient the following pathological features were
reported: variation in fibre size, split fibres and increased
activity of acid phosphatase. Electron microscopy (EM) re-
vealed accumulation of lipid, increased variation in mito-
chondrial size and shape, variation in myofibrilar diameter
and increased intermyofibrillar space [21]. The presence of
lipid droplets accumulation in oil-red-O histochemistry
was reported in another patient [23]. Diagnosis is con-
firmed by finding homozygous or compound heterozygous
mutations in ALDOA.
Beta Enolase 3 (ENO3)
Autosomal-recessive mutations in the ENO3 gene
(OMIM #131370) cause GSD XIII or muscle β-enolase de-
ficiency. β-enolase is a distal glycolytic enzyme.
Phenotype Symptoms of exercise intolerance are re-
ported to be milder than those seen in GSDV. There is no
second wind phenomenon. Symptoms include exercise-
induced myalgia and cramps [26,27].
Triggers for Rhabdomyolysis Strenuous exertion and
isometric muscle activity [27].
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between attacks of RM. Forearm exercise test shows a
suboptimal increase in serum lactate [27]. Muscle biopsy
examination under light microscopy may be unremarkable
while EM may show glycogen accumulation [26,27]. Bio-
chemical analysis of muscle tissue shows severely reduced
activity of β –enolase [26,27]. Diagnosis is confirmed by
genetic studies.
Phosphoglycerate Mutase 2 (PGAM2)
Autosomal-recessive mutations in the PGAM2 gene
(OMIM #612931) cause GSD type X, a metabolic myop-
athy characterized by the reduction of muscle phospho-
glycerate mutase (PGAM) resulting in a terminal block in
glycogenolysis. A mild residual activity of the brain iso-
form of the enzyme may be detected in muscle tissue.
Phenotype Symptoms are much milder than GSDV in
that symptoms are not present during most daily activ-
ities but can be precipitated by intense bursts of activity
[18,28-31]. There is no second wind phenomenon.
Triggers for Rhabdomyolysis Intense exertion such as
running and strength training exercise [28,29,31,32].
Diagnostic approach Serum CK is usually raised. Fore-
arm exercise test may show a mild suboptimal raise in lac-
tate [18,31]. Biochemical analysis of muscle tissue shows
reduced enzyme activity [31]. Muscle biopsy may show
tubular aggregates [28,29] and glycogen accumulation
[30]. Thus the triad of exercise-induced cramps, recurrent
myoglobinuria and tubular aggregates on muscle biopsy
should alert the clinician to the possibility of PGAM defi-
ciency [29].
Phosphoglycerate Kinase 1 (PGK1)
Phosphoglycerate kinase 1 (PGK) deficiency (OMIM #300653)
is an X-linked disorder characterized by the reduction of
phosphoglycerate kinase 1, which catalyses the conversion
of 1,3-diphosphoglycerate to 3-phosphoglycerate.
Phenotype Marked clinical variability has been described,
including haemolytic anaemia, muscle cramps and myalgia,
weakness, increased serum CK levels, exercise intolerance,
RM and central nervous system (CNS) manifestations in-
cluding mental retardation and development delay [33-36].
Triggers for Rhabdomyolysis Intense exercise [33,35,36].
Diagnostic approach Serum CK may be raised or within
normal range. Full blood count showing reticulosis and
mildly raised serum bilirubin may suggest haemolysis.
Forearm exercise test shows suboptimal rise in lactate
with exaggerated rise in ammonia [35,36]. Muscle biopsyfindings may be unremarkable [33,36] or show minor
changes such as fibre atrophy [35]. EM may reveal glyco-
gen accumulation [35,37]. Biochemical analysis shows
decreased PGK enzyme activity in muscle, erythrocytes
[35-37], white cells and platelets [35].
Phosphoglucomutase 1 (PGM1)
Recessive mutations in PGM1 (OMIM #171900) cause
GSD type XIV or phosphoglucomutase 1 deficiency, a clin-
ically heterogeneous multisystem disorder with features of
a metabolic disorder and a congenital disorder of glycosyl-
ation [5].
Phenotype A recent study reviewed the clinical phenotype
of GSDXIV [5]. Reported symptoms include endocrine
disorders, liver disease, bifid uvula, cleft palate, growth re-
tardation, hypogonadic hypogonadism, hypoglycaemia
and cardiomyopathy. Muscle symptoms include exercise
intolerance, weakness and RM [5]. Bifid uvula and liver
disease were the most common features recently reported
by Tegtmeyer et al. (2014) [5].
Triggers for Rhabdomyolysis Strenuous exercise [5,38].
Malignant hyperthermia and RM were reported in one
patient after halothane administration [39]. The combin-
ation of propofol and remifentanil caused mild raised
CK in the same patient [39].
Diagnostic approach Serum CK may be raised. Serum
transferrin isoforms are abnormal [5]. Incremental exercise
test until exhaustion on a cycle ergometer may show nor-
mal elevation of serum lactate levels [38]. Muscle biopsy
may show glycogen accumulation and reduction of phos-
phoglucomutase activity on biochemical evaluation [38].
Phosphorylase Kinase, Muscle, Alpha-1 Subunit (PHKA1),
Phosphorylase Kinase, Liver, Alpha-2 Subunit (PHKA2),
Phosphorylase Kinase, Beta Subunit (PHKB), Phosphorylase
Kinase, Testis/Liver, Gamma-2 (PHKG2)
Mutations in the PHKB, PHKA1, PHKA2, PHKG2 genes
(encoded by chromosome 16, X, X and 16 respectively)
cause GSD type IX, characterized by the deficiency of phos-
phorylase kinase (PK) resulting in impairment of glycogen
metabolism. PK has four subunits differentially expressed
in different tissues and encoded by different genes. Symp-
tomatic muscle PK deficiency may be seen in association
with PHKB (OMIM #172490) and PHKA1 (OMIM #311870)
mutations, although a mild transitory form of muscle weak-
ness and myalgia after strenuous exertion has been re-
cently reported in two patients with PHKG2 mutations
[40]. The phosphorylation of phosphorylase b into its ac-
tive form (phosphorylase a) is catalysed by the PK [41].
Thus muscle symptoms of GSDIX shares similar symp-
toms with GSDV, but they are usually milder. Here we will
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to affect the skeletal muscle isoform.
Phenotype Hepatomegaly, hypoglycemia following fast-
ing and growth delay are the primary presenting symp-
toms of mutations in PHKB [42], although mild muscle
symptoms occur. Muscle symptoms associated with muta-
tions in PHKA1 are usually mild and include exercise-
induced myalgia and cramps, fatigue and myoglobinuria
[43,44]. Raised CK following statin use was reported in as-
sociation with PHKA1 in one patient [44].
Triggers for Rhabdomyolysis Intense exertion
(PHKA1) [43,45].
Diagnostic approach Serum CK may be raised in be-
tween episodes of RM [46]. Muscle histology may show
nonspecific abnormalities and free glycogen accumula-
tion [43,46]. PK activity is reduced in muscle. Reduced
enzyme activity in erythrocytes may be seen but normal
values do not exclude the condition. Forearm exercise
test may show an exaggerated increase in ammonia but
a normal lactate response [44].
Disorders of fatty acid metabolism
Lipids are an important energy source of skeletal muscle
during endurance exercise, recovery following physical
exertion and when at rest. Different enzymes participate
in long-chain fatty acid breakdown in mitochondria.
Beta-oxidation of long chain fatty acids differs from
mitochondrial disorders, where primary downstream ef-
fect usually directly impair oxidative phosphorylation,
ultimately reducing ATP production as described below
(mitochondrial disorders section). Defects in the beta-
fatty acid oxidation pathway lead to disorders of fatty
acid metabolism, frequently characterized by exercise in-
tolerance, muscle pain and episodes of RM related to
prolonged aerobic exercise and other triggers such as
fever, fasting, stress, drugs (such as sodium valproate
and statins) and certain anaesthetic drugs. RM may also
be related to exertion when resumed after rest following
the onset of symptoms.
Propofol Infusion Syndrome (PIS) is a rare condition fol-
lowing the administration of high doses of propofol.
Symptoms include a wide range of systemic complications
such as cardiovascular, respiratory, metabolic, and hepatic
dysfunction [47]. RM may be seen in association with PIS.
Young age, high dose of propofol, concomitant adminis-
tration of vasopressor and underlying critical illness are
considered risk factors for PIS. Inborn errors of mitochon-
drial fatty acid oxidation have been listed as risk factors
for PIS [47] although the pathogenic mechanism is not
fully understood.ACYL-CoA Dehydrogenase, Very long-chain (ACADVL)
Homozygous or compound heterozygous mutations in
the ACADVL gene (OMIM #609575) cause a metabolic
myopathy due to very long-chain acyl-CoA dehydrogen-
ase (VLCAD) deficiency, an enzyme associated with the
inner mitochondrial membrane that plays an important
role in the first step of mitochondrial long chain fatty
acid oxidation.
Phenotype Varies in severity depending upon age of pres-
entation and includes three main clinical presentations: 1)
severe neonatal/early-childhood onset form presenting
with cardiomyopathy, hepatic disease and hypotonia with
high mortality in infancy, 2) milder childhood onset form
with hypoketotic hypoglycaemia, hypotonia with or with-
out hepatic disease and 3) adult-onset form presenting
with exercise intolerance, muscle cramps and RM [48,49].
However, there may be some symptom overlap between
the three clinical forms and RM has also been reported in
the mild childhood onset form [48] which may evolve into
an adult onset phenotype with age. Patients presenting
with the adult-onset form may have symptoms between
episodes of RM [49]. Severity and genotype may be corre-
lated, corresponding to the mutation-dependent level of
the residual enzyme activity (for example, severe early-
childhood onset form with no residual enzyme activity is
associated with the homozygous R429W mutation) [48].
Triggers for Rhabdomyolysis Fasting, prolonged aer-
obic exercise, emotional stress, shivering and cold, or
other catabolic stress such as infections and fever [49-51]
and certain drugs such as sodium valproate and statins.
Diagnostic approach Serum CK may be normal or raised
between attacks and may vary considerably between separ-
ate measurements. Muscle biopsy is unhelpful and should
not be performed if VLCAD is suspected, instead the most
important first line investigation is fasting blood acyl-
carnitine profile which shows accumulation of long-chain
acyl-carnitines usually with prominent C14:1. Functional
testing of fatty acid oxidation studies in skin fibroblasts is
abnormal. Diagnosis is confirmed by finding homozygous
or compound heterozygous mutations in ACADVL.
Carnitine Palmitoyltransferase II (CPT2)
Autosomal-recessive mutations in the CPT2 gene
(OMIM #600650) cause carnitine palmitoyl-transferase-II
(CPT-II) deficiency, the most common disorder of fatty acid
oxidation. CPT-II deficiency is characterized by reduced or
absent enzyme activity depending on the genotype.
Phenotype The clinical phenotypes are very similar to
VLCAD deficiency with three main forms: 1) fatal neonatal
form presenting with dysmorphic features, severe skeletal
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with hepatic, cardiac and skeletal muscle involvement with
hypoketotic hypoglycemia and 3) late (juvenile or adult)
onset with myalgia, exercise intolerance and recurrent RM
[52-54]. Importantly, enzyme defect and a more severe
phenotype have been correlated with certain genotypes
(for example, homozygous p.R631C and heterozygous null
mutations in trans with a second mutation) [53].
Triggers for Rhabdomyolysis Prolonged exercise, fever,
heat shock, infection, high fat intake, fasting, exposure
to cold, emotional stress, drugs including sodium valproate
and statins [53] and lipid soluble intravenous anaesthetic
drugs [52]. A malignant hyperthermia-like syndrome was
described in association with the heterozygous (R503C)
mutation following succinylcholine and halothane admin-
istration [55].
Diagnostic approach As with VLCAD, CK may be nor-
mal in between episodes and muscle biopsy is not help-
ful and should not be performed if CPT-II deficiency is
suspected. Fasting blood acyl-carnitine profile may show
accumulation of long-chain acyl-carnitines usually with
prominent C16, C18:1, C18 and is the preferred first line
investigation. Enzyme activity may be assessed in muscle
tissue, platelets/leukocyte and skin biopsy (cultured fi-
broblasts). Diagnosis is confirmed by finding mutations
in CPT2, however approximately 60% of affected people
carry the common (c.338C > T, p.Ser113Leu): thus, test-
ing of this specific mutation is recommended as a sec-
ond line investigation [56].
Electron Transfer Flavoprotein, Alpha Polypeptide (ETFA),
Electron Transfer Flavoprotein, Beta Polypeptide (EFTB),
Electron Transfer Flavoprotein Dehydrogenase (ETFDH)
Autosomal-recessive mutations in the EFTA (OMIM
#608053), EFTB (OMIM #130410) and ETFDH genes
(OMIM #231675) cause glutaric aciduria type II (GAII
or multiple acyl-coenzyme A dehydrogenase deficiency),
a metabolic condition characterized by the deficiency of
the alpha or beta subunits of electron transfer flavopro-
tein or the electron transfer flavoprotein dehydrogenase.
GAII results in a metabolic disturbance usually associ-
ated with acidosis due to the inability to breakdown fatty
acids (mitochondrial fatty acid oxidation) and amino
acids to generate energy. Choline metabolism is also af-
fected. As a result, metabolism and excretion of organic
acids such as glutaric acid are impaired.
Phenotype May vary according to age of presentation
with essentially three main forms: 1) neonatal-onset form
presenting with hypotonia, hepatomegaly, hypoglycaemia
and metabolic acidosis in association with congenital ab-
normalities such as dysmorphism and polycystic kidneysand high mortality in infancy, 2) neonatal-onset form with
no congenital abnormalities and 3) late-onset form pre-
senting with a wide spectrum of symptoms including my-
opathy, metabolic acidosis and hypoglycaemia [52,57].
Muscle symptoms include myalgia, weakness, exercise in-
tolerance and RM [57-61]. Muscle weakness may respond
to riboflavin given orally. Cardiomyopathy may be seen in
all forms [15].
Triggers for Rhabdomyolysis Reported triggers for RM
are physical exercise, fasting, irregular diet or infection
[58]. Triggers for metabolic decompensation may also in-
clude sodium valproate therapy, weight loss, alcohol in-
take and febrile illness [57].
Diagnostic approach Increased fasting urine organic
acids (glutaric acid, ethylmalonic acid, isovaleric acid, a-
methylbutyrate, isobutyrate, aliphatic dicarboxylic acids,
and their derivatives) and plasma acyl-carnitine profile (in-
creased C4-C12) may confirm the diagnosis when evaluated
during a metabolic stress episode [59]. Plasma free carnitine
level may be decreased [15]. Muscle biopsy may show lipid
accumulation and enlarged mitochondria [15,57,58].
Mitochondrial disorders
Mitochondria are highly dynamic organelles that provide
cellular energy, in the form of adenosine triphosphate
(ATP), via oxidative phosphorylation. Since skeletal muscle
tissue has very high energy requirements, it is particularly
sensitive to impaired mitochondrial function.
Mitochondrial diseases usually refer to genetic defects
whose primary downstream effect directly impairs oxidative
phosphorylation which ultimately reduces ATP production.
However, a number of additional essential metabolic pro-
cesses occur within mitochondria, such as beta-oxidation of
long chain fatty acids. Mutations in genes encoding en-
zymes involved with beta-oxidation disrupt mitochondrial
fatty acid oxidation and include CPT-II and VLCAD defi-
ciency, both of which are discussed above.
The clinical presentation of mitochondrial disorders is
extremely variable. This is, in part, due to the large num-
ber of genetic causes implicated in the development of
disease. One important, although relatively infrequent,
manifestation of mitochondrial disease is RM. Table 1
summarizes a few examples of genes associated with mito-
chondrial dysfunction and RM.
Phenotype Multisystem features vary according to the
genetic mutation and may include cardiomyopathy, liver
disease, Leber hereditary optic neuropathy, bowel dysmo-
tility, Leigh syndrome, developmental delay and mental
retardation. Muscle symptoms may include myopathy, fa-
tigue, exercise intolerance, myalgia, limb and facial weak-
ness, recurrent RM episodes and muscle cramps [62-71].
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and viral illness have been associated with RM, although
often it may not be possible to identify a specific trigger
[64,66,67,69,71]. Mitochondrial dysfunction has been
considered to play an important role in PIS (see above,
disorders of fatty acid metabolism section), although the
pathogenic mechanisms of PIS are not fully understood
yet. PIS has been recently associated with Leber heredi-
tary optic neuropathy [72] and POLG1 [73] although the
reported patients had more than one risk factor for PIS.
Further studies are needed to confirm a genetic predis-
position for PIS.
Diagnostic approach Serum CK may be normal or raised.
In one patient acyl-carnitine profile mimicked acyl-CoA de-
hydrogenase deficiency in COII mutation (m.8156dupG
mutation) [71]. Raised serum lactate may be seen at rest
and following exercise [63,64]. Muscle biopsy may reveal
ragged red fibres, cytochrome c oxidase (COX)-negative fi-
bres and subsarcolemmal accumulation of mitochondria.
Ragged red fibres staining positive for COX and succinate
dehydrogenase (SDH) may be seen in association with a
cytochrome b gene defect [63,64]. Reduced SDH activity,
patchy COX deficiency, iron accumulation and ultrastruc-
turally abnormal mitochondria containing electron dense
inclusions have been associated with iron-sulfur cluster as-
sembly enzyme [15,67]. Nonspecific myopathic features
may be seen. Analysis of respiratory chain enzymes may
help the diagnosis. First line investigation for mtDNA com-
mon mutations may be performed in a blood sample but
usually skeletal muscle is required to sequence mtDNA for
cases presenting with RM.
Disorders of intramuscular calcium release and
excitation-contraction coupling
Excitation-contraction coupling (ECC), i.e. the effective
translation of an electrical neuronal impulse into muscle
contraction, is an intricate process involving several
intramuscular ion channels and pumps. The key players
involved in ECC are the voltage-gated dihydropyridine re-
ceptor localized on the transverse tubules, the ligand-
gated skeletal muscle ryanodine receptor (RyR1) localized
on the sarcoplasmic reticulum, and various sarcoendoplas-
mic reticulum (SR) calcium transport ATPases (SERCAs).
Although neuromuscular phenotypes have been associated
with all 3 proteins, RYR1-related neuromuscular disorders
are by far the most common and may also feature RM
episodes.
Ryanodine Receptor 1 (RYR1)
Mutations in the RYR1 gene (OMIM#180901) cause a wide
spectrum of neuromuscular phenotypes, ranging from the
dominantly inherited MHS trait [74] to various congenital
myopathies, including dominantly inherited Central CoreDisease [75] and subgroups of recessively inherited Multi-
minicore Disease [76], Centronuclear Myopathy [77] and
Congenital Fibre Type Disproportion [78]. RYR1 encodes
the principal SR calcium release channel with a crucial role
in skeletal muscle excitation-contraction (E-C) coupling.
Phenotype A wide range of neuromuscular features may
be seen in association with RYR1 mutations, including
hypotonia, developmental delay, facial weakness with or
without ptosis and extraocular muscle involvement, axial
and proximal muscle weakness. However, RYR1-related
(exertional) rhabdomyolysis occurs mainly in individuals
with MHS-associated RYR1 mutations who rarely exhibit
any muscle weakness, but rather on the contrary, may ex-
hibit muscle hypertrophy and even superior athletic abil-
ities. In addition to exertion-induced RM, myalgia, muscle
stiffness and heat intolerance are common in this group of
patients [3,75]. King-Denborough syndrome and late-onset
axial myopathy are other myopathic manifestations closely
associated with MHS-related RYR1mutations [79,80].
Triggers for Rhabdomyolysis Heat, exercise, anaesthetic
(MHS), muscle relaxants (MHS), drugs and alcohol but
not fasting. Exercise is the most common trigger, but
often a combination of factors appears to be required to
trigger an episode [3,81]. In contrast to some of the meta-
bolic conditions outlined above, RM episodes events may
occur hours (occasionally days) after intense and unaccus-
tomed exercise. Infection may unmask MHS-related RYR1
mutations [3,4] and may be an underdiagnosed cause of
RYR1-related rhabdomyolysis.
Diagnostic approach Muscle pathology findings may
vary. A recent review of patients presenting with rhabdo-
myolysis due to (mainly MHS-associated) dominant RYR1
mutation showed that muscle biopsy findings were often
non-specific, but may feature “RYR1-compatible” findings
including irregular internal architecture or core-like struc-
tures, increased internal nuclei, type 1 fibre predomin-
ance and pinprick fibres expressing neonatal myosin [3].
Muscle magnetic resonance imaging (MRI) findings in the
same cohort often showed marked muscle hypertrophy
corresponding to clinical features [3], but not the pattern
of selective involvement typically seen in RYR1-associated
congenital myopathies [4], in keeping with the divergent
clinical phenotypes.
Muscular dystrophies
Muscular dystrophies (MD) represent a clinically and gen-
etically heterogeneous group of disorders characterized by
progressive weakness and skeletal muscle degeneration.
There is an increased susceptibility for muscle damage
and RM may be seen in association with exertion but the
timing of onset of symptoms with duration of exercise is
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nuria may be the presenting symptom of an underlying
MD even before weakness becomes clearly manifest [82].
Becker muscular dystrophy (BMD) due to mutations in
DMD and limb-girdle muscular dystrophy 2I (LGMD2I)
due to mutations in FKRP (OMIM#606596) are the most
common dystrophies to present with RM [82]. RM and
myalgia may be the dominating symptom in a few cases of
LGMD2I [82]. RM as the presenting symptom of MDs
has also been reported in association with sarcoglycanopa-
thies, dysferlinopathies [83,84] and the more recently re-
ported conditions related to recessive mutations in ANO5.
Recessive mutations in ANO5 (OMIM#608662) cause a
wide spectrum of myopathies including LGMD2L, distal
myopathy and isolated hyperCKemia. Exercise intolerance,
severe myalgia, variable muscle weakness and RM have
been associated with ANO5 [85,86], although specific trig-
gers for RM could not be elicited [85]. Identification of
amyloid deposition on muscle biopsy is a clue for the diag-
nosis of an anoctaminopathy [85,86]
Thus, unexplained RM occurring in the context of a
history of exertion myalgia should also raise the suspi-
cion of MDs, even if no weakness is clearly manifest.
Figure 1 and Table 1 summarises the main MDs associ-
ated with RM [8,83,85-90].Miscellaneous
LPIN1
Autosomal-recessive mutations in the LPIN1 gene
(OMIM #605518) have been reported as the second
most common cause of early-onset RM [91]. Impaired
lipid synthesis of triglycerides and membrane phospho-
lipids as well as energetic defect have all been hypothe-
sised as pathogenic mechanisms for RM in this disorder,
although the exact mechanism remains unclear [92].Phenotype Early onset usually before 6 years with a mean
age of onset of approximately 21 months [91,92] with se-
vere episodes of RM with high mortality [92,93]. Myalgia
and stiffness may be seen during acute episodes of RM
[93]. Episode frequency may decrease with age [92].Triggers for Rhabdomyolysis Fever, general anaesthesia,
fasting [91,92].Diagnostic approach Between episodes serum CK and
acyl-carnitine profile may be normal. Muscle biopsy can
be normal or it can show lipid accumulation. Type I fibre
predominance, type II fibre atrophy and ragged-red fibres
have been reported [15,91,94]. Genetic testing is required
to confirm the diagnosis.SIL1, S. Cerevisiae, Homolog Of (SIL1)
Autosomal-recessive mutations in SIL1 (OMIM #608005)
cause Marinesco-Sjogren syndrome, a multisystem dis-
order with consistent neuromuscular involvement.
Phenotype Cataracts, cerebellar atrophy and ataxia are
usually seen in association with different multisystem signs
and symptoms. Neuromuscular findings include hypotonia,
development delay, weakness, a variably associated periph-
eral neuropathy, and, rarely, RM [15,95,96].
Triggers for Rhabdomyolysis Infection [95,97].
Diagnostic approach Muscle biopsy may show a broad
spectrum of myopathic features including rimmed vacuoles,
increase in connective tissue with fat infiltration, ragged
red fibres and type I fibre predominance. EM may show
unique dense membranes/tubules surrounding the muscle
fibre nucleus [15].
tRNA Splicing Endonuclease 54, S. Cerevisiae, Homolog Of
(TSEN54)
Pontocerebellar hypoplasia type 2 (PCH-2) is a neurode-
generative disorder characterized by hypoplasia and at-
rophy of pons and cerebellum in association with other
CNS manifestations. Recent reports suggest a myopathic
component in PCH-2, including RM that has been re-
ported in association with mutations in the TSEN54 gene
(OMIM #608755).
Phenotype Global developmental delay, microcephaly,
epilepsy, movement disorders and other CNS manifesta-
tions may be seen. Muscle symptoms include hyperCK-
aemia and RM [98,99].
Triggers for Rhabdomyolysis Febrile infections and
hyperthermia [98,99].
Diagnostic approach Brain MRI may confirm the CNS
abnormalities. Muscle biopsy may be normal or show
fibre atrophy on light microscopy. EM may show abnor-
malities including sarcomeric disruption and Z-band ab-
normalities even in patients where light microscopy is
normal [98].
Genetic Polymorphisms and association with RM
In addition to the genetic conditions detailed above, dif-
ferent genetic polymorphisms have already been associ-
ated with CK elevations, however it is not entirely clear
if the same polymorphisms also confer a higher risk for
RM, as contradictory findings have been reported. One
example of such contradiction is the I allele in the angio-
tensin I-converting enzyme (ACE) gene which has been
previously associated with increased CK levels after
Table 2 Polymorphisms previously reported to be associated with exercise related muscle injury
Gene Exercise related symptoms rs# (dbSNP) Comments Ref
ACE Increased CK levels following eccentric
exercise
rs4340 Dose dependent increase of CK (II higher than ID) [102]
No association rs4340 - [101]
No association rs4340 - [100]
ACTN3 Exertion rhabdomyolysis rs1815739 TT genotype [100]
No association with CK/Mb changes rs1815739 TT genotype – lower baseline CK [104]
CCL2 Exercise-induced skeletal muscle
damage following maximal
eccentric exercise
rs3917878, rs13900,
rs1024611, rs1860189
rs3917878 – high CK response (women) and attenuated strength
recovery (men) rs13900, rs1024611 and rs1860189 - abnormal
preexercise CK level (women)
[106]
CCR2 Exercise-induced skeletal muscle
damage following maximal
eccentric exercise
rs3918358, rs768539,
rs1799865,
rs3918358 – slower strength recovery (women) rs1799865 – soreness
rs1799865 – abnormal preexercise CK level (women) rs768539 and
rs3918358 – preexercise strength (men)
[106]
CKMM Exertion rhabdomyolysis rs1803285 GG genotype [100]
Increased CK following exertion rs1803285 AA genotype [101]
IGF-II Muscle damage following maximal
isotonic eccentric contractions
rs3213221, rs680,
rs7924316, rs2132570
Strength loss, soreness and high CK (Muscle damage indicators) [105]
IL6 Increased CK levels following
maximal eccentric exercise
rs13447445 Dose dependent increase of CK (CC higher than CG genotypes) [107]
No association rs13447445 - [100]
MYLK No association rs2700352 - [100]
Muscle damage following
maximal eccentric exercise
rs2700352,
rs28497577
GG has greater increase in CK and myoglobin following exercise,
higher baseline strength AC greater increase CK following exercise,
postexercise strength loss (no AA data)
[104]
Exertion rhabdomyolysis rs28497577 AC or AA [100]
TNFA Increased CK levels following
maximal eccentric exercise
rs361525 Mild association [107]
CK: creatine kinase, I: insertion - I allele; D: deletion - D allele; Ref: reference.
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authors [100-102]. The same has been observed with the
R577X ACNT3 variant: the XX genotype, which has been
reported in athletes [103], was also associated with low
muscle strength and low resting CK [104] and exertional
RM [100].
These intriguing findings emphasise the complexity of
RM pathophysiology and the need for further studies to
clarify the role of polymorphisms in muscle breakdown.
Table 2 summarises a few genetic polymorphisms previ-
ously reported in association with CK elevations and
muscle symptoms [100-102,104-107].
Conclusion
Inherited muscle disorders associated with RM are het-
erogeneous and rare. Much of the current knowledge
concerning these conditions is based on individual case
reports. Within the group of inherited muscle disorders,
RM occurs most frequently in disorders of muscle metab-
olism (most commonly due to mutations in ACADVL,
CPT2 and PYGM), mitochondrial dysfunction, muscular
dystrophies (most commonly seen in BMD and LGMD2I),
congenital myopathies where intracellular calciumhomeostasis and excitation-contraction coupling are af-
fected (RYR1) and LPIN1. Awareness of specific genotype-
phenotype correlations in genetic conditions associated
with RM is of importance to inform the diagnostic ap-
proach. In individual cases, RM events may reflect a com-
bination of a genetic predisposition and environmental
triggers, and the presence of an identifiable trigger does
not necessarily exclude an underlying genetic cause.
A substantial proportion of patients presenting with RM
remain currently genetically unsolved, suggesting add-
itional pathogenic mechanisms not yet discovered. Poly-
morphisms causing an additive effect in the pathogenesis
of RM have been suggested by different authors but may
prove difficult to confirm. New diagnostic techniques such
as next generation sequencing and whole exome/genome
sequencing may help to evaluate patients for comprehen-
sive gene sets concomitantly as well as identifying new
genetic causes of RM [108,109].
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